Skip to main content Skip to main navigation menu Skip to site footer
Review
Published: 14-01-2022

Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections

Centro Universitário FAM, São Paulo, Brazil
Universidade de Sorocaba, São Paulo, Brazil
Universidade São Judas Tadeu (USJT), São Paulo, Brazil
Universidade São Judas Tadeu (USJT), São Paulo, Brazil
antibiotics Clostridioides difficile intestinal microbiota

Abstract

Objective: This study aimed to perform a comprehensive review of clinical trials using fecal microbiota transplantation in cases of Clostridioides difficile infection. Methods: This manuscript reviews clinical studies published from 2003 to 2020 at the Scientific Electronic Library Online (SciELO Brazil), Latin American and Caribbean Health Sciences Literature (LILACS) and US National Library of Medicine (MedLine/PubMed) databases using the descriptors antibiotic/antimicrobial, Clostridium difficile/Clostridioides difficile, intestinal microbiota/intestinal microbiome and fecal transplantation. Results: Interventions on microbiota include the use of probiotics, prebiotics, and fecal microbiota transplantation as therapeutic methods. Results show that fecal microbiota transplantation is an excellent alternative for the treatment of recurrent C. difficile infections.

Metrics

Metrics Loading ...

References

  1. Podolsky SH. Metchnikoff and the microbiome. Lancet 2012; 380 (9856): 1810-1811 DOI: 10.3389/fpubh.2013.00052.
  2. Tannock GW. The normal microflora: an introduction. In: Tannock GW. Medical importance of the normal microflora. Netherlands: Kluwer Academic Publishers; 1999: 1-23
  3. Malozi MC. A importância da microbiota no sistema imunológico. Rev Pediatr Mod 2012
  4. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015; 21 (29) 8787-8803 DOI: 10.3748/wjg.v21.i29.8787.
  5. Harmsen HJ, de Goffau MC. The Human Gut Microbiota. Adv Exp Med Biol 2016; 902: 95-108 DOI: 10.1007/978-3-319-31248-4_7.
  6. Neuman H, Forsythe P, Uzan A, Avni O, Koren O. Antibiotics in early life: dysbiosis and the damage done. FEMS Microbiol Rev 2018; 42 (04) 489-499 DOI: 10.1093/femsre/fuy018.
  7. Hills Jr RD, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients 2019; 11 (07) 1613 DOI: 10.3390/nu11071613.
  8. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006 Dec 21;444(7122): 1027-1031 DOI: 10.1038/nature05414.
  9. Fontané L, Benaiges D, Goday A, Llauradó G, Pedro-Botet J. Influence of the microbiota and probiotics in obesity. Clin Investig Arterioscler 2018 Nov-Dec; 30 (06) 271-279 DOI: 10.1016/j.arteri.2018.03.004.
  10. Penteado JO, Salgado RGF, Barlem E. A eficácia do tratamento da obesidade através do transplante da microbiota fecal de indivíduos magros. Rev Cienc Saude 2017; 29 (01) 46-53
  11. Nuriel-Ohayon M, Neuman H, Koren O. Microbial Changes during Pregnancy, Birth, and Infancy. Front Microbiol 2016; 7: 1031 DOI: 10.3389/fmicb.2016.01031.
  12. Clark A, Mach N. Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes. J Int Soc Sports Nutr 2016; 13 (43) 43 DOI: 10.1186/s12970-016-0155-6.
  13. Cekanaviciute E, Yoo BB, Runia TF. et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A 2017; 114 (40) 10713-10718 DOI: 10.1073/pnas.1711235114.
  14. Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med 2019; 11 (02) e9302 DOI: 10.15252/emmm.201809302.
  15. Sulis G, Pai M. Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLoS Med 2020; 17 (01) e1003023 DOI: 10.1371/journal.pmed.1003023.
  16. Paixão LA, Castro FFS. Colonização da Microbiota Intestinal e sua Influência na Saúde do Hospedeiro. Universitas: Ciências da Saúde 2016; 14 (01) 85-96 DOI: 10.5102/UCS.V14I1.3629.
  17. Almeida LB, Marinho CB, Souza CS, Cheib VBP. Disbiose Intestinal. Braz J Clin Nutr 2009; 24 (01) 58-65
  18. Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease. Ageing Res Rev 2018; 45: 53-61 DOI: 10.1016/j.arr.2018.04.004.
  19. Carreiro DM, Carreiro PS. O ecossistema intestinal na saúde e na doença. São Paulo: Vida & Consciência; 2014
  20. Satokari R, Fuentes S, Mattila E, Jalanka J, de Vos WM, Arkkila P. Fecal transplantation treatment of antibiotic-induced, noninfectious colitis and long-term microbiota follow-up. Case Rep Med 2014; 2014 (Nov): 913867 DOI: 10.1155/2014/913867.
  21. Li Z, Zhu H, Zhang L, Qin C. The intestinal microbiome and Alzheimer's disease: A review. Animal Model Exp Med 2018; 1 (03) 180-188 DOI: 10.1002/ame2.12033.
  22. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe 2016; 40: 95-99 DOI: 10.1016/j.anaerobe.2016.06.008.
  23. Guh AY, Kutty PK. Clostridioides difficile Infection. Ann Intern Med 2018; 169 (07) ITC49-ITC64 DOI: 10.7326/AITC201810020.
  24. Silva Júnior M. Recentes mudanças da infecção por Clostridium difficile . Einstein (Sao Paulo) 2012; 10 (01) 105-109
  25. Mörkl S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the Microbiota-Gut-Brain Axis: Focus on Psychiatry. Curr Nutr Rep 2020; 9 (03) 171-182 DOI: 10.1007/s13668-020-00313-5.
  26. Brüssow H. Probiotics and prebiotics in clinical tests: an update. F1000 Res 2019; 8: 1157 DOI: 10.12688/f1000research.19043.1.
  27. Rezaeiasl Z, Salami M, Sepehri G. The Effects of Probiotic Lactobacillus and Bifidobacterium Strains on Memory and Learning Behavior, Long-Term Potentiation (LTP), and Some Biochemical Parameters in β-Amyloid-Induced Rat's Model of Alzheimer's Disease. Prev Nutr Food Sci 2019; 24 (03) 265-273 DOI: 10.3746/pnf.2019.24.3.265.
  28. Gazerani P. Probiotics for Parkinson's Disease. Int J Mol Sci 2019; 20 (17) 1-26 DOI: 10.3390/ijms20174121.
  29. Collins FL, Rios-Arce ND, Schepper JD, Parameswaran N, McCabe LR. The Potential of Probiotics as a Therapy for Osteoporosis. Microbiol Spectr 2017; 5 (04) 1-16 DOI: 10.1128/microbiolspec.BAD-0015-2016.
  30. Ticinesi A, Nouvenne A, Cerundolo N. et al. Gut Microbiota, Muscle Mass and Function in Aging: A Focus on Physical Frailty and Sarcopenia. Nutrients 2019; 11 (07) 1633 DOI: 10.3390/nu11071633.
  31. Ge X, Zhao W, Ding C. et al. Potential role of fecal microbiota from patients with slow transit constipation in the regulation of gastrointestinal motility. Sci Rep 2017; 7 (01) 441 DOI: 10.1038/s41598-017-00612-y.
  32. Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine 2019; 44: 716-729 DOI: 10.1016/j.ebiom.2019.05.066.
  33. Leshem A, Horesh N, Elinav E. Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome. Front Immunol 2019; 10: 1341 DOI: 10.3389/fimmu.2019.01341.
  34. Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer 2019; 145 (08) 2021-2031 DOI: 10.1002/ijc.32003.
  35. Lopez J, Grinspan A. Fecal Microbiota Transplantation for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 2016; 12 (06) 374-379
  36. Xu MQ, Cao HL, Wang WQ. et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015; 21 (01) 102-111 DOI: 10.3748/wjg.v21.i1.102.
  37. Duda JR. Transplante de fezes: Procedimento é utilizado para tratar tipo de colite [internet]. Minha Vida, 2016. Disponível em: https://www.minhavida.com.br/saude/tudo-sobre/20618-transplante-de-fezes
  38. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44 (05) 354-360 DOI: 10.1097/MCG.0b013e3181c87e02.
  39. Brasil. Ministério da Saúde. Doação de Órgãons: transplantes, lista de espera e como ser doador. Disponível em: http://www.saude.gov.br/saude-de-a-z/doacao-de-orgaos
  40. Horvat S, Rupnik M. Interactions Between Clostridioides difficile and Fecal Microbiota in in Vitro Batch Model: Growth, Sporulation, and Microbiota Changes. Front Microbiol 2018; 9: 1633 DOI: 10.3389/fmicb.2018.01633.
  41. Brown KA, MacDougall LK, Valenta K. et al. Increased environmental sample area and recovery of Clostridium difficile spores from hospital surfaces by quantitative PCR and enrichment culture. Infect Control Hosp Epidemiol 2018; 39 (08) 917-923 DOI: 10.1017/ice.2018.103.
  42. Gerding DN, Sambol SP, Johnson S. Non-toxigenic Clostridioides (Formerly Clostridium) difficile for Prevention of C. difficile Infection: From Bench to Bedside Back to Bench and Back to Bedside. Front Microbiol 2018; 9: 1700 DOI: 10.3389/fmicb.2018.01700.
  43. Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H. Clostridium difficile, the Difficult “Kloster” Fuelled by Antibiotics. Curr Microbiol 2019; 76 (06) 774-782 DOI: 10.1007/s00284-018-1543-8.
  44. Cheng YW, Phelps E, Ganapini V. et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant 2019; 19 (02) 501-511 DOI: 10.1111/ajt.15058.
  45. Jiang ZD, Ajami NJ, Petrosino JF. et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther 2017; 45 (07) 899-908 DOI: 10.1111/apt.13969.
  46. Hota SS, Sales V, Tomlinson G. et al. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial. Clin Infect Dis 2017; 64 (03) 265-271 DOI: 10.1093/cid/ciw731.
  47. Kelly CR, Khoruts A, Staley C. et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. Ann Intern Med 2016; 165 (09) 609-616 DOI: 10.7326/M16-0271.
  48. Ramsauer B, König C, Sabelhaus T, Ockenga J, Otte JM. Fecal Microbiota Transplantation in Relapsing Clostridium Difficile Colitis. MMW Fortschr Med 2016; 158 (Suppl. 04) 17-20 DOI: 10.1007/s15006-016-8305-y.
  49. Lee CH, Steiner T, Petrof EO. et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2016; 315 (02) 142-149 DOI: 10.1001/jama.2015.18098.
  50. Orenstein R, Dubberke E, Hardi R. et al; PUNCH CD Investigators. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis 2016; 62 (05) 596-602 DOI: 10.1093/cid/civ938.
  51. Ponte A, Pinho R, Mota M. et al. Initial experience with fecal microbiota transplantation in Clostridium difficile infection - transplant protocol and preliminary results. Rev Esp Enferm Dig 2015; 107 (07) 402-407 DOI: 10.17235/reed.2015.3767/2015.
  52. Youngster I, Sauk J, Pindar C. et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58 (11) 1515-1522 DOI: 10.1093/cid/ciu135.

How to Cite

Signorette, J. P., Oliveira, R. T. D. de, Montiel, J. M., & Longo, P. L. (2022). Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections. International Journal of Nutrology, 14(1), 16–20. https://doi.org/10.1055/s-0040-1718996